KABI-2161
N/A
Report date: 2022/01/14 13:23:58
NME
Base Information
Drug NameKABI-2161
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A
Develop Information
Other Information
ATC CodeN/A
Related LinksN/A